COMP <GO>
ALKS vs AMRX // RSI-14 & 200D SMA MOMENTUM
Alkermes plc (NASDAQ) VS. Amneal Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ALKS 7
— AMRX 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: AMRX
LAST: $44.89 (-0.99%) • MKT CAP: $7.61B
rsi-technicals
61.0
LAST: $20.44 (-4.97%) • MKT CAP: $7.49B
rsi-technicals
66.6
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALKS VS. AMRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALKS | AMRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.70% | 36.90% | +49.80 | ALKS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.00% | 14.10% | -0.10 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.1x | 21.4x | +3.70 | AMRX | /valuation <GO> |
| Free Cash Flow Yield | 6.31% | 3.63% | +2.68 | ALKS | /fcf-yield <GO> |
| Operating Margin | 17.20% | 13.10% | +4.10 | ALKS | /operating-margins <GO> |
| Net Profit Margin | 16.40% | 2.40% | +14.00 | ALKS | /net-margins <GO> |
| Revenue Growth (YoY) | -5.20% | 8.00% | -13.20 | AMRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.03 | 3.83 | +4.20 | ALKS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 61.0 | 66.6 | -5.60 | AMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.08 | -0.03 | AMRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.3x | 96.0x | -66.70 | ALKS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.61B | $7.49B | $114.5M | ALKS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALKS REV | AMRX REV | ALKS GROSS % | AMRX GROSS % | ALKS FCF | AMRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.48B | $3.02B | 86.7% | 36.9% | $480.3M | $269.9M |
| FY 2024 | $1.56B | $2.79B | 84.2% | 36.5% | $405.6M | $243.2M |
| FY 2023 | $1.66B | $2.39B | — | — | $326.5M | $237.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALKS // BETA 1.05
AMRX // BETA 1.08